Press & News

The next generation biopharmaceuticals

Press releases 2019

2019-07-16

Affibody Announces Interim Analysis in Phase 2 Psoriasis Trial of ABY-035

Solna, Sweden, July 16, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced the completion of the planned 12 week interim analysis in the Company’s Phase 2 proof-of-concept study of its bispecific molecule ABY-035 for moderate-to-severe psoriasis (“AFFIRM-35”).[read more]

Older press releases

2019-06-17

Affibody to Present at Affinity 2019

Solna, Sweden, June 17, 2019. Affibody AB (“Affibody”), a clinical stage biotech company, today announced that Prof. Fredrik Frejd, CSO, will present at the Affinity 2019 conference in June.[read more]

2019-05-27

Notice of AGM (Kallelse till årsstämma)

Aktieägarna i Affibody Medical AB (publ) kallas härmed till årsstämma tisdagen den 25 juni 2019 klockan 16.30 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.[read more]

2019-05-27

Affibody Enters into Agreement with 3P Biopharmaceuticals for Production of ABY-035

Solna, Sweden, May 27, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company, today announced an agreement with 3P Biopharmaceuticals (“3P”) covering process development and GMP manufacturing of Affibody’s ABY-035 drug.[read more]

Affibodys latest Press releases

2019-07-16

Affibody Announces Interim Analysis in Phase 2 Psoriasis Trial of ABY-035

Solna, Sweden, July 16, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report Q1 (May 17, 2019)

Investor information